Information Provided By: 
Fly News Breaks for March 20, 2019
ALXN
Mar 20, 2019 | 14:49 EDT
After attending Alexion's investor day meeting, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating and said he remains a buyer of the stock, stating that he sees the company's two newly announced collaborations with Zealand Pharma and Affibody as a continuation of a recent trend of "bolt-on deals with good strategic logic." He came away from the meeting with increased confidence in management's strategy and ability to execute given data pointing to robust Soliris-to-Ultomiris conversion and rapid Soliris gMG uptake, Raymond added.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
